Stockholm, April 15, 2025 - The European Commission has today communicated that it has granted BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's application for Marketing Authorization ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

The European Commission has approved the antibody lecanemab to treat Alzheimer's, the first time it has authorized a therapy which targets the underlying disease processes, rather than just the ...

The European Commission has for the first time approved an Alzheimer's therapy that targets the underlying disease processes. Lecanemab, an antibody, is for early-stage treatment and is the first drug ...